drugset / Trial / NCT00035113

EPO906 Therapy in Patients With Prostate Cancer

NCT00035113

Phase 2 Completed 48 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause prostate cancer.

Timeline

Start
2002-01
Primary completion
2004-01
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule Intravenous

Indications